Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Phase 3 Update: TRIUMPH-4 Results Preliminary data from the ongoing Phase 3 TRIUMPH-4 trial (68 weeks) shows higher numbers than Phase 2: 12mg dose: 28.7% average weight loss (~71 lbs / 32 kg) 9mg dose: 26.4% average weight loss (~64 lbs / 29 kg) Knee osteoarthritis pain: 76% reduction (significant quality-of-life improvement) Blood pressure: Average reduction of 14 mmHg Full Phase 3 results across the TRIUMPH program (obesity, diabetes, cardiovascular outcomes, kidney outcomes) are expected throughout 2026
Gupta sees diarrhea frequently as well, but she acknowledges this may be confusing, considering many people also experience the opposite symptom
However, the definitive Exenatide-PD3 phase 3 trial , published in The Lancet in February 2025, found no disease-modifying benefit exenatide did not slow Parkinsons progression over 96 weeks compared to placebo in 194 patients ( [25] )
IGF-I is involved in neuronal myoblast proliferation and differentiation, and organ development
US$ 24.78
US$ 27.59
US$ 27.94
US$ 21.86
.png)
US$ 24.02
US$ 24.91
